Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.14 (2.99%)
Data as of 05/06/16 2:26 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
05/05/16Exelixis to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10Printer Friendly Version
05/04/16Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate UpdatePrinter Friendly Version
04/26/16Exelixis to Release First Quarter 2016 Financial Results on Wednesday, May 4, 2016Printer Friendly Version
04/25/16Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic TherapyPrinter Friendly Version
Upcoming EventsMore >>
Exelixis, Inc. at Bank of America Merrill Lynch 2016 Health Care Conference
Tuesday, May 10, 2016 8:00 a.m. PT
LocationLas Vegas, NV
Add to Calendar Add Exelixis, Inc. at Bank of America Merrill Lynch 2016 Health Care Conference to Calendar  Help
remind me days before the event

Enter your e-mail address 
Featured Report
Download Documentation2015 Annual Report (pdf)
Download Documentation2014 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.